"The study of 18 patients is the first to show that the drug does not require the presence of herpes simplex virus 2 (HSV-2) to suppress HIV in patients. The researchers hope to confirm their results in a larger study.
"These findings ar"...
DOSAGE AND ADMINISTRATION
Recommended Dosage For Adult Patients
The recommended dosage of EPIVIR in HIV-1-infected adults is 300 mg daily, administered as either 150 mg taken orally twice daily or 300 mg taken orally once daily with or without food. If lamivudine is administered to a patient infected with HIV-1 and HBV, the dosage indicated for HIV-1 therapy should be used as part of an appropriate combination regimen [see WARNINGS AND PRECAUTIONS].
Recommended Dosage For Pediatric Patients
The recommended dosage of EPIVIR oral solution in HIV-1-infected pediatric patients aged 3 months and older is 4 mg per kg taken orally twice daily or 8 mg per kg taken orally once daily (up to a maximum of 300 mg daily), administered in combination with other antiretroviral agents. Consider HIV-1 viral load and CD4+ cell count/percentage when selecting the dosing interval for patients initiating treatment with oral solution [see CLINICAL PHARMACOLOGY].
EPIVIR is also available as a scored tablet for HIV-1-infected pediatric patients who weigh at least 14 kg and for whom a solid dosage form is appropriate. Before prescribing EPIVIR tablets, children should be assessed for the ability to swallow tablets. If a child is unable to reliably swallow EPIVIR tablets, the oral solution formulation should be prescribed. The recommended oral dosage of EPIVIR tablets for HIV-1-infected pediatric patients is presented in Table 1.
Table 1: Dosing Recommendations for EPIVIR Scored
(150-mg) Tablets in Pediatric Patients
|Weight (kg)||Once-daily Dosing Regimena||Twice-daily Dosing Regimen Using Scored 150-mg Tablet|
|AM Dose||PM Dose||Total Daily Dose|
|14 to < 20||1 tablet (150 mg)||½ tablet
|≥ 20 to < 25||1/ tablets (225 mg)||½ tablet
|≥ 25||2 tablets (300 mg)b||1 tablet
|a ding the efficacy of once-daily dosing is
limited to subjects who transitioned from twice-daily dosing to once-daily
dosing after 36 weeks of treatment [see Clinical Studies].
b Patients may alternatively take one 300-mg tablet, wData regarhich is not scored.
Patients With Renal Impairment
Dosing of EPIVIR is adjusted in accordance with renal function. Dosage adjustments are listed in Table 2 [see CLINICAL PHARMACOLOGY].
Table 2: Adjustment of Dosage of EPIVIR in Adults and
Adolescents (Greater than or Equal to 25 kg) in Accordance with Creatinine
|Creatinine Clearance (mL/min)||Recommended Dosage of EPIVIR|
|> 50||150 mg twice daily or 300 mg once daily|
|30-49||150 mg once daily|
|15-29||150 mg first dose, then 100 mg once daily|
|5-14||150 mg first dose, then 50 mg once daily|
|< 5||50 mg first dose, then 25 mg once daily|
Although there are insufficient data to recommend a specific dose adjustment of EPIVIR in pediatric patients with renal impairment, a reduction in the dose and/or an increase in the dosing interval should be considered.
Dosage Forms And Strengths
- EPIVIR Scored Tablets
150 mg, are white, diamond-shaped, scored, film-coated tablets debossed with “GX CJ7” on both sides.
- EPIVIR Tablets
300 mg, are gray, modified diamond-shaped, film-coated tablets engraved with “GX EJ7” on one side and plain on the reverse side.
- EPIVIR Oral Solution
A clear, colorless to pale yellow, strawberry-banana flavored liquid, containing 10 mg of lamivudine per 1 mL.
Storage And Handling
EPIVIR Scored Tablets, 150 mg
White, diamond-shaped, scored, film-coated tablets debossed with “GX CJ7” on both sides. Bottle of 60 tablets (NDC 49702-203-18) with child-resistant closure.
EPIVIR Tablets, 300 mg
Gray, modified diamond-shaped, film-coated tablets engraved with “GX EJ7” on one side and plain on the reverse side.
Bottle of 30 tablets (NDC 49702-204-13) with child-resistant closure.
Store EPIVIR Tablets at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].
EPIVIR Oral Solution, 10 mg per mL
A clear, colorless to pale yellow, strawberry-banana-flavored liquid, contains 10 mg of lamivudine in each 1 mL.
Plastic bottle of 240 mL (NDC 49702-205-48) with child-resistant closure. This product does not require reconstitution.
Store in tightly closed bottles at 25°C (77°F) [see USP Controlled Room Temperature].
Manufactured for: ViiV Healthcare, Research Triangle Park, NC 27709. by: GlaxoSmithKline, Research Triangle Park, NC 27709. Revised: Sep 2015This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 10/23/2015
Additional Epivir Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.